Open AccessAcute profound abciximab induced thrombocytopenia: a correct management of a methodological error
Author(s) -
Gaetano Tanzilli,
Martina Sordi,
Alessio Arrivi,
E Madon,
Massimiliano Scappaticci
Publication year - 2009
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr.12.2008.1381
Subject(s) - medicine , abciximab , clopidogrel , discontinuation , percutaneous coronary intervention , antiplatelet drug , eptifibatide , complication , platelet transfusion , unstable angina , surgery , aspirin , platelet , anesthesia , cardiology , myocardial infarction
Thrombocytopenia is a rare complication of glycoprotein IIb/IIIa treatment. We report a case of an acute profound abciximab induced thrombocytopenia and its successful management. The patient, presenting with unstable angina, underwent percutaneous coronary intervention with implantation of three drug eluting stents without receiving a clopidogrel loading dose according to guidelines. The rapid drop in the platelet count after abciximab elastomeric pump infusion was treated with drug discontinuation and platelet transfusion. The high risk of stent thrombosis was avoided by a timely readministration of the dual antiplatelet treatment.